Optimizing intensive care management in paediatric sepsis

Current Opinion in Infectious Diseases

Volumn 22, Issue 3, 2009, Pages 264-271

  Rooney, Zoe ^a   Nadel, Simon ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Intensive care; Paediatric; Sepsis

Indexed keywords

CATECHOLAMINE; DEXAMETHASONE; DROTRECOGIN; MANNITOL; MILRINONE; VACCINE; VASOPRESSIN;

ADD ON THERAPY; ASSISTED VENTILATION; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BLEEDING; BRAIN HERNIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; ENTEROBACTERIACEAE; EXTRACORPOREAL OXYGENATION; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERGLYCEMIA; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE MONITORING; LABORATORY TEST; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PEDIATRIC SEPSIS; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; VENTILATOR; VITAL SIGN; CASE MANAGEMENT; PATHOLOGY;

CASE MANAGEMENT; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; SEPSIS;

EID: 65549145812     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328329c493     Document Type: Review

References (55)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
2. Cunnington A, Nadel S. New therapies for sepsis. Curr Top Med Chem 2008; 8:603-614. A comprehensive review of the rationale and efficacy of novel therapies.
3. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701.
4. Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO estimates of the causes of death in children. Lancet 2005; 365:1147-1152.
5. Paediatric Intensive Care Audit Network National Report 2004-2005. Universities of Leeds, Leicester and Sheffield; 2006.
6. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5:975-979.
7. Aird WC. Endothelium as an organ system. Crit Care Med 2004; 32:S271-S279.
8. Levy RM, Prince JM, Billiar TR. Nitric oxide: a clinical primer. Crit Care Med 2005; 33:S492-S495.
9. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417-430.
10. Macias WL, Yan SB, Williams MD, et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; 9:S38-S45.
11. Karimova A, Pinsky DJ. The endothelial response to oxygen deprivation: biology and clinical implications. Intensive Care Med 2001; 27:19-31.
12. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678-681.
13. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunstion in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
14. Brierley J, Choong K, Cornell T, et al. 2007 Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666-688. Evidence-based update of the 2002 guidelines that are the basis for most sepsis treatment protocols for children in the developed world.
15. 2 assessment of CO in children with fluid-resistant shock. Different patterns of shock were noted in different aetiologies, suggesting targeted therapy.
16. MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38:284-288.
17. Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:793-799.
18. Inwald DP, Tasker R, Peters MJ, Nadel S. Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch Dis Child 2009; doi:10.1136/adc.2008. 153064 [Epub ahead of print]. Important audit of the management of patients with sepsis referred to PICUs in the UK. Increased risk of mortality was associated with failure to reverse shock by the time of PICU admission. Importantly, most patients in whom shock was not reversed had management that was not according to the 2002 American College of Critical Medicine/Pediatric Advanced Life Support (ACCM/PALS) guidelines (see [14).
19. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266:1242-1245.
20. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
21. 2 of at least 70% has a significant and additive impact on the outcome of children with septic shock.
22. Ledingham IM, McArdle CS. Prospective study of the treatment of septic shock. Lancet 1978; 1:1194-1197.
23. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85:386-390.
24. Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch Dis Child 2001; 85:382-385.
25. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
26. Schortgen F, Girou E, Deye N, Brochard L, for the CRYCO Study Group. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008; 34:2157-2168. Important study comparing hyperoncotic fluids such as starch and 20% albumin with hypooncotic fluids such as crystalloid and 5% albumin. The study confirmed a significant risk of nephrotoxicity with the use of hyperoncotic fluids.
27. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887. A novel study demonstrating no clear difference in mortality with the use of vasopressin versus noradrenaline in adults with septic shock.
28. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.
29. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107:996-1002.
30. 2, suggesting that a mechanism relatively independent of macrocirculatory haemodynamics and overall microvascular perfusion might account for these observations.
31. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308.
32. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999; 282:54-61.
33. Eisner MD, Thompson T, Hudson LD, et al., Acute Respiratory Distress Syndrome Network. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164:231-236.
34. Pollard AJ, Nadel S, Ninis N, et al. Emergency management of meningococcal disease: eight years on. Arch Dis Child 2007; 92:283-286.
35. Day KM, Haub N, Betts H, Inwald DP. Hyperglycemia is associated with morbidity in critically ill children with meningococcal sepsis. Pediatr Crit Care Med 2008; 9:636-640. Important study demonstrating that there is an association between morbidity and peak glucose level in children with meningococcal septicaemia.
36. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr 2005; 146:30-34.
37. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
38. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461.
39. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and penta-starch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139. In this study, the use of intensive insulin therapy placed critically ill patients with sepsis at significantly increased risk for serious adverse events related to hypoglycaemia, without any effect on survival.
40. Davies MS, Nadel S, Habibi P, et al. The orthopaedic management of peripheral ischaemia in meningococcal septicaemia in children. J Bone Joint Surg Br 2000; 82:383-386.
41. Allport T, Read L, Nadel S, Levin M. Critical illness and amputation in meningococcal septicemia: is life worth saving? Pediatrics 2008; 122:629-632. The degree of amputation in children with meningococcal disease did not predict the functional outcome. The surprisingly good outcomes reported should discourage clinicians from withdrawing intensive care support because of presumed poor outcomes after multiple amputations.
42. Sáez-Llorens X, McCracken GH Jr. Bacterial meningitis in children. Lancet 2003; 361:2139-2148.
43. Wakai A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev 2005:CD001049.
44. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
45. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341.
46. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843.
47. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
48. Lipiner-Friedman D, Sprung CL, Laterre PF, et al. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007; 35:1012-1018.
49. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
50. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124. In this landmark study to examine the widespread use of hydrocortisone replacement therapy guided by corticotrophin stimulation testing, hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not have a response to corticotropin, although hydrocortisone hastened the reversal of shock in patients in whom shock was reversed. This has reversed the consensus that low-dose hydrocortisone is beneficial to patients with septic shock.
51. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997; 278:925-931.
52. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 2004; 4:139-143.
53. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
54. Maclaren G, Butt W, Best D, et al. Extracorporeal membrane oxygenation for refractory septic shock in children: one institution's experience. Pediatr Crit Care Med 2007; 8:447-451.
55. Ninis N, Phillips C, Bailey L, et al. The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and nonfatal cases. BMJ 2005; 330:1475.